Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Being a boy, having lower depression and anxiety scores, lower headache intensity, lower affective pain perception, fewer pain locations, fewer sleep issues, and lower pain-related disability predicted headache remission. 

Study Identifies Factors Preceding Headache Remission in Adolescents

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 12, 2024. 

NeurologyLive® Friday 5 — April 12, 2024

Videos

The director of the Brain Health Imaging Institute in the department of radiology at Weill Cornell Medicine talked about using a novel radiotracer to understand the movement of fluids and waste products in the brain. [WATCH TIME: 5 minutes]

Utilizing a Radiotracer to Shed Light on Brain Fluid Dynamics: Mony de Leon, EdD

ALKS 2680, an investigational orexin 2 receptor agonist, showed promise for improving sleep latency in patients with narcolepsy type 2 and idiopathic hypersomnia in a phase 1b study.

ALKS 2680 Significantly Improves Wakefulness for Narcolepsy Type 2 and Idiopathic Hypersomnia in Phase 1b Trial

, has been with the team since September 2022. Follow her on Twitter 

The executive vice president and chief research officer of the Muscular Dystrophy Association shared her reaction to the recent FDA approval of givinostat for Duchenne muscular dystrophy.

NeuroVoices: Sharon Hesterlee, PhD, on Givinostat’s Approval for Duchenne Muscular Dystrophy, Future Prospects

Manager of Health Literacy at National MS Society.

Elizabeth Miller, MA, the manager of health literacy at the National MS Society, discussed the impact of health literacy in the multiple sclerosis community. 

Advancing Equity and Inclusion: Health Literacy for the MS Community and Beyond

The chief of neurology and co-director of the Neurological Institute at the Children’s Hospital Los Angeles provided insight on the barriers to prevent neurodevelopmental disorders and the lack of currently validated biomarkers. [WATCH TIME: 4 minutes]

Challenges in Identifying Markers for Neurodevelopmental Disorders: Shafali Jeste, MD

, has been with the team since October 2019. Follow him on Twitter 

Advancements in the detection and care of multiple sclerosis have led to improved diagnosis rates and a more multidisciplinary approach to treating the autoimmune disorder.

Diagnosing, Treating, and Preventing Multiple Sclerosis: Marcus Institute Gold Standard Center

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Slideshows

What neuropsychiatric conditions are relatives of people with ALS at risk for? Are other genes involved besides C9orf72?

Clinical

Neuropsychiatric Disorders and Amyotrophic Lateral Sclerosis